There are currently 224 clinical trials in Santa Monica, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Citruslabs, Clinical Science Institute, Sarcoma Oncology Center and John Wayne Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Pa0016 50672, Santa Monica, California
Conditions: Psoriatic Arthritis
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue. The main objective of the study is to learn about the effect litifilimab h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Clinical Science Institute, Santa Monica, California
Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Recruiting
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Angeles Clinic and Research Institute, Santa Monica, California
Conditions: Melanoma
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/12/2025
Locations: Clinical Science Institute, Santa Monica, California
Conditions: Atopic Dermatitis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Ps0039 50642, Santa Monica, California
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Recruiting
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: St. John's Cancer Center, Santa Monica, California
Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. These types of study drugs are collectively known as immune checkpoint inhibitors. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: St John's Cancer Institute, Santa Monica, California
Conditions: Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
Recruiting
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the bra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: St John's Cancer Institute, Santa Monica, California
Conditions: Melanoma
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Recruiting
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of California Los Angeles, Santa Monica, California
Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Sarcoma Oncology Research Center, Santa Monica, California
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
HAELO: a Phase 3 Study to Evaluate NTLA-2002 in Participants with Hereditary Angioedema (HAE)
Recruiting
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in adult participants with HAE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Raffi Tachdjian MD, Inc, Santa Monica, California
Conditions: Hereditary Angioedema
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/11/2025
Locations: Study site, Santa Monica, California
Conditions: Hereditary Angioedema (HAE)